SANGAMO THERAPEUTICS INC (SGMO)

Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics.

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

Why Is Sangamo Therapeutics (SGMO) Stock Up 52% Today?

Sangamo Therapeutics stock is heading higher on Tuesday as SGMO investors react to a new $50 million license agreement.

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

Why Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?

Little-known firm Sangamo Therapeutics is surging today, with SGMO stock up more than 40% on promising late-stage trial results.

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

Major Potential: 5 NASDAQ / NYSE Stocks Under $1 SGMO, FTCI, VTAK, SPRB, DNA

Commit To Purchase Sangamo Therapeutics At $0.50, Earn 59.8% Annualized Using Options

SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024

SGMO stock results show that Sangamo Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

SGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sangamo Therapeutics (NASDAQ:SGMO) just reported results for the first quarter ...

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Notable Monday Option Activity: MTTR, IBM, SGMO